OTC Markets OTCPK - Delayed Quote ? USD Galera Therapeutics, Inc. (GRTX) Follow Compare 0.0490 +0.0005 (+1.03%) At close: November 6 at 3:00 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Galera Announces Board Approval of Complete Liquidation and Dissolution Company reports second quarter 2024 financial resultsMALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors has approved a Plan of Liquidation and Dissolution (Plan of Dissolution), which provides for the dissolution of the Company unde GlobeNewswire ? 2 months ago GRTX +1.03% Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates Company’s evaluation of potential strategic alternatives progresses with goal to maximize stockholder valueMALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the first quarter ended March 31, 2024, and provided recent corporate updates. "Our review of GlobeNewswire ? 5 months ago GRTX +1.03% Galera Adopts Limited Duration Stockholder Rights Agreement MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors (the “Board”) has unanimously resolved to adopt a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests. The Board resolved to adopt the Rights Agreement in res GlobeNewswire ? 6 months ago GRTX +1.03% Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates Company continues to evaluate strategic options to maximize shareholder valueMALVERN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the fourth quarter and year ended December 31, 2023 and provided recent corporate updates. "As a result of last year’s FDA request for a GlobeNewswire ? 7 months ago GRTX +1.03% Galera Therapeutics Insiders Lose Out As Stock Sinks To US$0.17 The recent 19% drop in Galera Therapeutics, Inc.'s ( NASDAQ:GRTX ) stock could come as a blow to insiders who purchased... Simply Wall St. ? 9 months ago GRTX +1.03% Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended Se GlobeNewswire ? 11 months ago GRTX +1.03% Performance Overview Trailing total returns as of 11/6/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return GRTX S&P 500 YTD -66.21% +24.30% 1-Year -57.39% +36.04% 3-Year -97.42% +26.22%
